Transarterial Chemoembolization Market Share

Global Transarterial Chemoembolization (TACE) Market Overview

Transarterial Chemoembolization (TACE) Market Size was valued at USD 10.9 Billion in 2022. The Transarterial Chemoembolization (TACE) market industry is projected to grow from USD 11.4 Billion in 2023 to USD 16.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.90% during the forecast period (2023 - 2032). Rising drug consumption and development, as well as rising liver cancer incidence, are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Transarterial Chemoembolization (TACE) Market Trends

• Rising incidence of liver cancer is driving the market growth

Transarterial chemoembolization (TACE) market growth is expected to be fueled by the rising incidence of liver cancer. HCC is the second leading cause of cancer mortality in men worldwide and the fifth most frequently diagnosed malignancy overall. In Asia and Africa, high-grade cervical cancer is more prevalent. Hepatocellular carcinoma is a primary tumour of the liver that most frequently results from cirrhosis and long-term liver issues. The illness is the third-leading  cause of cancer mortality and affects over 500,000 people worldwide. The current gold standard of care for treating people with intermediate-stage hepatocellular carcinoma is transarterial chemoembolization (HCC). TACE is therefore viewed as standard treatment for HCC in the traditional sense.

For the treatment of liver cancer, transarterial chemoembolization is used. The idea behind how it works is to stop the tumor's blood supply. Chemotherapy is given directly into the tumour when a supply has been cut off. Hepatocellular carcinoma patients in the intermediate stage receive intravenous treatment. In the US, conventional transarterial chemoembolization is regarded as the gold standard treatment for HCC. During transarterial chemoembolization, it is also feasible to use microspheres as drug transporters, which may reduce the amount of chemotherapeutics in the patient's systemic circulation.

Over the coming years, it is hoped that new transarterial chemoembolization products (TACE) and combination therapies (DEB-TACE) will transform the way that HCC is treated. The untapped HCC market is projected to grow as new drugs are introduced in both first- and second-line situations. The HCC market will grow after new product introductions in both first- and second-line settings. In order to advance the TACE technology, new biodegradable microspheres have been created and are currently undergoing testing. They are made to keep post-TACE target artery access intact, enabling the possibility of cyclic treatment. The development of TACE is likely to continue in a number of directions, including those that are currently "under construction" and aimed at bettering patient selection, developing new tools to standardise treatment, increasing selectivity to administer chemotherapeutic agents more precisely while sparing the non-tumor liver, or combining treatments with recently created immune therapy agents.

Since indications occasionally overlap, new advancements in the field of selective internal radiation treatment (SIRT) will also have an impact on the future of TACE. In this era of systemic treatments with unheard-of outcomes and high tolerance, the findings of recent research will direct the development of TACE. To accommodate various clinical requirements, numerous kinds of micro catheters and micro guidewires are offered. As an illustration, the effectiveness and safety of the recently discovered balloon-occluded transarterial chemoembolization (B-TACE) of hepatocellular carcinoma (HCC) utilising miriplatin (a lipophilic anticancer medication) and gelatin particles. • In a similar vein, patients with hepatocellular carcinoma (HCC) experienced superior clinical results following balloon-occluded transcatheter arterial chemoembolization employing a balloon micro-catheter and epirubicin-loaded polyethylene-glycol (PEG) microsphere (100 + 25 m and 200 +50 m). Thus, driving the Transarterial Chemoembolization (TACE) market revenue.

Transarterial Chemoembolization (TACE) Market Segment Insights

Transarterial Chemoembolization (TACE) Procedure Type Insights

The  Transarterial Chemoembolization (TACE) market segmentation, based on procedure type, includes conventional TACE and DEB-TACE. Conventional TACE segment dominated the market in 2022. The increasing prevalence of hepatocellular carcinoma can be attributed for this.

Transarterial Chemoembolization (TACE) Indication Insights

The  Transarterial Chemoembolization (TACE) market segmentation, based on indication, includes unresectable HCC and early-stage HCC. The unresectable HCC segment dominated the market in 2022. This is explained by rising medicine use and exponential growth.

Transarterial Chemoembolization (TACE) Product Type Insights

The  Transarterial Chemoembolization (TACE) market segmentation, based on product type, includes chemotherapeutic agents, radiotherapeutic agents, drug-eluting particles, and others. Chemotherapeutic agents segment dominated the  transarterial chemoembolization (TACE) market in 2022. This is brought on by the rising incidence of HCC, which has been steadily rising as a result of smoking and other immune-stressing factors.

Transarterial Chemoembolization (TACE) End User Insights

The Transarterial Chemoembolization (TACE) market segmentation, based on End User, includes hospitals & clinics, cancer research centers, and others. The hospital & clinics segment dominated the Transarterial Chemoembolization (TACE) market in 2022. This is brought on by the rise in hospital operations, favourable government spending, and improved cancer management. Transarterial Chemoembolization (TACE) Market Value is being driven up by patients in specialty clinics and other market segments.

Figure 1  Trans arterial Chemoembolization (TACE) Market, by End User, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Transarterial Chemoembolization (TACE) Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Transarterial Chemoembolization (TACE) Market dominated this market in 2022 (45.80%). This is attributable to factors such as steadily rising HCC cases, rising investment, the development of innovative medication delivery technologies, and the existence of significant market participants in the area. A number of strategic acquisitions have been made by the majority of the big players in the developed regions, increasing their market share over time. Further, the U.S. Transarterial Chemoembolization (TACE) market held the largest market share, and the Canada Transarterial Chemoembolization (TACE) market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Transarterial Chemoembolization (TACE) market accounted for the healthy market share in 2022. One of the major factors driving the expansion of the transcatheter arterial chemoembolization market is the rising cancer prevalence in the area. Better local cancer control, better treatment results, and advanced ultra-selective TACE, which can be used to treat tiny HCCs, are all contributing factors to the expansion of the chemoembolization market in Europe. Further, the German Transarterial Chemoembolization (TACE) market held the largest market share, and the U.K Transarterial Chemoembolization (TACE) market was the fastest growing market in the European region

The Asia Pacific Transarterial Chemoembolization (TACE) market is expected to register significant growth from 2023 to 2032. TACE with a lipiodol-chemotherapeutic drug suspension and gelatin sponge (GS) particles are heavily marketed in the Asia Pacific region. The demand for conventional TACE (cTACE) is extremely high here. On the other side, TACE treatments that employ drug-eluting beads (a form of DEB called DEBDOX that may bind doxorubicin, or DEB-TACE) are primarily encouraged. Moreover, China’s Transarterial Chemoembolization (TACE) market held the largest market share and the Indian Transarterial Chemoembolization (TACE) market was the fastest growing market in the Asia-Pacific region.

Transarterial Chemoembolization (TACE) Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Transarterial Chemoembolization (TACE) market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Transarterial Chemoembolization (TACE) industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Transarterial Chemoembolization (TACE) industry to benefit clients and increase the market sector. In recent years, the Transarterial Chemoembolization (TACE) industry has offered some of the most significant advantages to medicine. Major players in the Transarterial Chemoembolization (TACE) market, including Advaxis Inc., Baxter, Bellicum Pharmaceuticals, Boston Scientific Corporation, Cook, Hikma Pharmaceuticals PLC, Isofol Medical AB, Nippon Kayaku Co., Novartis, Pfizer, Sirtex SIR-Spheres Pty Ltd., and Spectrum Pharmaceuticals, are attempting to increase market demand by investing in research and development Products.

A biopharmaceutical firm called Merck & Co Inc (Merck) is dedicated to the discovery, development, production, and marketing of prescription drugs, biologic therapies, vaccines, and animal health products. It provides products on prescription for the treatment of conditions like diabetes, cancer, immunological diseases, cardiovascular disease, and cancer. The business offers vaccinations, poultry, cattle, and aquaculture products, among other animal health items. Merck provides managed healthcare services to hospitals, government organisations, wholesalers, retailers, and hospitals. It also provides veterinarians, distributors, and animal producers with animal health products. Operating in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America are the company and its subsidiaries. Outside of North America and Canada, Merck is known as MSD, and its main office is in Kenilworth, New Jersey. Update on Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma was published in February 2023 by Merck Sharp & Dohme LLC in collaboration with Eisai Inc.

AstraZeneca Plc (AstraZeneca) is a biopharmaceutical firm that focuses on the development, manufacturing, and marketing of a variety of prescription medications. It creates goods for the treatment of ailments like cancer, autoimmune, infectious, neurological, and respiratory, cardiovascular, renal, and metabolic problems. Vaccines, prescription medications, and biologics are all part of the company's product line. Through distributors, local representative offices, and wholly-owned local marketing firms, AstraZeneca offers its products. The business sells its goods to general practitioners and specialists in medicine. Operating regions for the corporation include Europe, the Americas, Asia, Africa, and Australasia. The U.K.'s Cambridge, in Cambridgeshire, serves as the company's headquarters. An update to Evaluation of Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1) was published by AstraZeneca in April 2023.

Key Companies in the Transarterial Chemoembolization (TACE) market include

• Advaxis Inc.


• Baxter


• Bellicum Pharmaceuticals


• Boston Scientific Corporation


• Cook


• Hikma Pharmaceuticals PLC


• Isofol Medical AB


• Nippon Kayaku Co.


• Novartis


• Pfizer


• Sirtex SIR-Spheres Pty Ltd.


• Spectrum Pharmaceuticals

Transarterial Chemoembolization (TACE) Industry Developments

May 2023 Nivolumab with Ipilimumab and Nivolumab Alone in Combination With Trans-Arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W) is being evaluated by Bristol-Myers Squibb.

Transarterial Chemoembolization (TACE) Market Segmentation

Transarterial Chemoembolization (TACE) Procedure Type Outlook

• Conventional TACE


• DEB-TACE

Transarterial Chemoembolization (TACE) Indication Outlook

• Unresectable HCC


• Early-Stage HCC

Transarterial Chemoembolization (TACE) Product Type Outlook

• Chemotherapeutic Agents


• Radiotherapeutic Agents


• Drug-eluting Particles


• Others

Transarterial Chemoembolization (TACE) End User Outlook

• Hospitals & Clinics


• Cancer Research Centers


• Others

Transarterial Chemoembolization (TACE) Regional Outlook

• 
  North America
  
  
  
  • US.
  
  
  • Canada
  
  
  
  


• 
  Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• 
  Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America